KYMR Stock Risk & Deep Value Analysis
Kymera Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on KYMR
We analyzed Kymera Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran KYMR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈KYMR Performance Overview3yr weekly
Unlock KYMR Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
KYMR Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
About Kymera Therapeutics Inc (KYMR)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
mid
Market Cap
$7.24B
KYMR Deep Value Analysis
KYMR Red Flags & Warning Signs
Premium- ⚠
Clinical trial failure or unexpected safety signals for KT-474 or other key pipeline assets
- ⚠
Regulatory delays or non-approvals for lead candidates
- ⚠
Intensified competition leading to superior alternative therapies or earlier-to-market TPD assets from rivals
- ⚠
Increased cash burn without corresponding clinical progress requiring significant dilution.
Unlock KYMR Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
KYMR Financial Health Metrics
Market Cap
$7.24B
KYMR Competitive Moat Analysis
PremiumMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
Kymera's moat is primarily built on its proprietary TPD platform, growing IP portfolio around novel degraders and E3 ligases, and the significant clinical data being generated. The strategic partnerships also create a form of switching costs due to deep integration and shared R&D efforts. As its pipeline matures and more assets demonstrate clinical success, its platform's value and thus its moat will strengthen.
KYMR Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
KYMR Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated mid-March 2026)
- •KT-474 Phase 3 trial initiation/first patient enrollment update (Q1/Q2 2026)
- •Pre-clinical or early clinical data updates for KT-333 (STAT3 degrader) or KT-621 (IRAK4 degrader) from oncology pipeline.
Medium-Term (6-18 months)
- •Expansion of KT-474 into additional inflammatory indications (6-12 months post Phase 3 start)
- •Potential new strategic partnership for an earlier-stage asset or platform use (late 2026/early 2027)
- •Advancement of KT-333 or KT-621 into later-stage clinical trials.
Long-Term (18+ months)
- •KT-474 successful Phase 3 readout and regulatory submission (2028-2029)
- •Establishment of Kymera as a multi-product TPD leader across inflammatory and oncology indications
- •Continued platform validation leading to a sustainable drug discovery engine.
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
KYMR Bull Case: What Could Go Right
- ✓
Successful and timely initiation of KT-474 Phase 3, followed by positive interim data readouts
- ✓
Positive clinical data for earlier-stage oncology assets (KT-333, KT-621)
- ✓
Maintenance of strong cash position and disciplined capital allocation without excessive dilution.
Bull Case Analysis
See what could go right with Premium
Never miss a move on KYMR
Create a free account to set price alerts and get notified on Telegram when KYMR hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Kymera Therapeutics Inc (KYMR)?
As of February 28, 2026, Kymera Therapeutics Inc has a DVR Score of 7.0 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Kymera Therapeutics Inc?
Kymera Therapeutics Inc's market capitalization is approximately $7.2B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Kymera Therapeutics Inc use?
KYMR is the ticker symbol for Kymera Therapeutics Inc. The company trades on the NGM.
What is the risk level for KYMR stock?
Our analysis rates Kymera Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the KYMR DVR analysis updated?
Our AI-powered analysis of Kymera Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on February 28, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.